| ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade |
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-15 17:00:39 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates |
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2025-05-12 12:35:36 |
Czytaj oryginał (ang.) |
| ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025. With the issuance of the permanent J-code (J9028) in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter, with March. |
businesswire.com |
2025-05-12 10:30:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA |
ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX shares to around $2.00, but the trading volume was not extremely high. Despite the setback, I maintain a conviction level of 3 out of 5 for IBRX, focusing on potential long-term gains and upcoming catalysts. |
seekingalpha.com |
2025-05-05 21:05:05 |
Czytaj oryginał (ang.) |
| ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug |
ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. |
benzinga.com |
2025-05-05 13:21:28 |
Czytaj oryginał (ang.) |
| ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. This RTF letter was received despite reaching unanimous. |
businesswire.com |
2025-05-05 10:30:00 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:25 |
Czytaj oryginał (ang.) |
| ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish |
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. |
seekingalpha.com |
2025-04-29 16:50:12 |
Czytaj oryginał (ang.) |
| Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during an oral presentation at the American Urological. |
businesswire.com |
2025-04-28 12:30:00 |
Czytaj oryginał (ang.) |
| ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-29. The company will also host an educational and peer-networking event to discuss ImmunityBio's approa. |
businesswire.com |
2025-04-21 20:21:00 |
Czytaj oryginał (ang.) |
| ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, ImmunityBio completed the submission to the FDA of an sBLA for the use of ANKTIVA plus BCG in BCG-unrespon. |
businesswire.com |
2025-04-15 12:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immu. |
businesswire.com |
2025-04-08 11:30:00 |
Czytaj oryginał (ang.) |
| Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities |
SAN DIEGO , April 7, 2025 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. SECURITIES LITIGATION No. |
prnewswire.com |
2025-04-07 23:30:00 |
Czytaj oryginał (ang.) |
| ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company's research programs. The discus. |
businesswire.com |
2025-04-07 09:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: Taking Care Of Business |
ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but ImmunityBio's rBCG efforts could fill the supply gap and potentially redefine NMIBC treatment. Despite strong commercial momentum, ImmunityBio's financial health remains a concern, with a quarterly cash burn rate of $104.4M and a cash runway of less than four months. |
seekingalpha.com |
2025-04-03 21:54:49 |
Czytaj oryginał (ang.) |
| ImmunityBio to Host Investor Day |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with. |
businesswire.com |
2025-03-26 08:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum |
ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. |
seekingalpha.com |
2025-03-07 03:47:28 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates |
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-03-03 12:01:01 |
Czytaj oryginał (ang.) |
| ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the fourth-quarter and full year ended December 31, 2024. With the issuance of the permanent J-code in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter,. |
businesswire.com |
2025-03-03 09:30:00 |
Czytaj oryginał (ang.) |
| IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on August 29, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company. |
globenewswire.com |
2025-02-27 23:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: Forging A New Plan After Recent $100 Million Offering |
ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash burn rate and financial health remain concerns, but ANKTIVA's impressive performance and future milestones could drive substantial growth and extend the cash runway. IBRX's financial risks persist, and multiple offerings may be needed before profitability, but the potential for explosive revenue growth by 2029 supports a bullish outlook. |
seekingalpha.com |
2024-12-16 02:24:43 |
Czytaj oryginał (ang.) |
| ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success |
ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Despite recent setbacks, including a Q3 net loss of $80m and a cash position of $130m, I maintain a "Buy" rating, anticipating positive 2025 catalysts. Anktiva's efficacy in NMIBC and potential in NSCLC + other cancers are potentially compelling, but the company needs substantial funding to complete ongoing and planned clinical studies. |
seekingalpha.com |
2024-12-13 16:40:45 |
Czytaj oryginał (ang.) |
| D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering |
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares were sold by ImmunityBio. Before deducting the underwriting discount and offering expenses payable by ImmunityBio, ImmunityBio expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about December 12, 2024 subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-12-12 10:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of. |
businesswire.com |
2024-12-11 09:30:00 |
Czytaj oryginał (ang.) |
| ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. |
businesswire.com |
2024-12-10 18:24:00 |
Czytaj oryginał (ang.) |
| ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment |
FREMONT, Calif. , Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. |
prnewswire.com |
2024-11-21 12:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-19 12:56:21 |
Czytaj oryginał (ang.) |
| ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements |
SAN FRANCISCO , Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm. |
prnewswire.com |
2024-11-19 11:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates |
ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2024-11-12 11:41:11 |
Czytaj oryginał (ang.) |
| ImmunityBio Reports Third-Quarter 2024 Financial Results |
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical. |
businesswire.com |
2024-11-12 09:15:00 |
Czytaj oryginał (ang.) |
| IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company. |
globenewswire.com |
2024-10-30 23:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 |
ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Keytruda or Opdivo, showed promising results in phase 2b for NSCLC, leading to upcoming phase 3 studies. The company has around $130.1 million in cash, bolstered by a $100 million infusion, enough to fund operations for at least the next 12 months. |
seekingalpha.com |
2024-10-28 09:53:21 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? |
ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-28 07:10:38 |
Czytaj oryginał (ang.) |
| 800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio |
EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases. |
benzinga.com |
2024-10-23 19:35:52 |
Czytaj oryginał (ang.) |
| ImmunityBio to Participate in the Jefferies London Healthcare Conference |
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton London. Details of the presentation can be found below. Jefferies London Healthcare Conference Date: Tuesday, November 19, 2024 Time: 2:30 PM GT Format: Fireside chat with ImmunityBio company executives A replay of the recorded firesid. |
businesswire.com |
2024-10-21 13:00:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: Moving The Needle |
ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding. |
seekingalpha.com |
2024-10-07 15:18:00 |
Czytaj oryginał (ang.) |
| ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt |
Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls. |
seekingalpha.com |
2024-09-21 23:02:30 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That Are Set To Fly This Quarter |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2024-08-16 11:57:13 |
Czytaj oryginał (ang.) |
| ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal' |
ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high R&D costs. Analysts project peak revenues of ~$900m by 2028 for Anktiva, although at present, Immunity's pricing of the drug is a little hard to understand. |
seekingalpha.com |
2024-08-14 18:13:17 |
Czytaj oryginał (ang.) |
| ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates |
ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago. |
zacks.com |
2024-08-12 14:15:56 |
Czytaj oryginał (ang.) |